Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Detalles Bibliográficos
Autores principales: Kumada, Hiromitsu, Watanabe, Tsunamasa, Suzuki, Fumitaka, Ikeda, Kenji, Sato, Ken, Toyoda, Hidenori, Atsukawa, Masanori, Ido, Akio, Takaki, Akinobu, Enomoto, Nobuyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David, Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910493/
https://www.ncbi.nlm.nih.gov/pubmed/29134328
http://dx.doi.org/10.1007/s00535-017-1409-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910493/
https://www.ncbi.nlm.nih.gov/pubmed/29134328
http://dx.doi.org/10.1007/s00535-017-1409-z

Ejemplares similares